Document is current

Article History

Received: 15 August 2024

Revised: 4 December 2024

Accepted: 24 December 2024

First Online: 27 February 2025

Ethics approval

: This study was conducted in accordance with International Conference on Harmonization Good Clinical Practice (ICH GCP) guidelines and the Declaration of Helsinki. This study protocol was reviewed and approved by relevant ethics committees or institutional review boards (IRBs) at each site in accordance with ICH GCP and applicable country-specific requirements. Ethics committees or IRB names (investigator number/centre number) were as follows: Comite de Protection des Peronnes Ile de France XI (362722/242514); University Hospitals Case Medical Centre (434586/247088); Greenville Hospital System (265348/243157); Dana-Farber Cancer IRB (22606/243147); Dana-Farber Cancer IRB (22606/242642); IntegReview IRB (169995/243149); UCLA Office of the Human Research Protection Program (017855/247875); Advarra (012120/243367); Advarra (432930/247089); IntegReview IRB (021368/243145); Advarra (208365/243155); IntegReview IRB (417524/243142); IntegReview IRB (415147/243150); Baylor Scott and White Research Institute Institutional Review Board (202669/247850). All patients provided written informed consent before participation in the study.

: JRH received consulting fees from Corcept, Astellas, Gilead, Istari, Gritstone, Exelixis, Deciphera, Galvanize, IGM, Taiho, Bristol Myers Squibb, Novartis, Oncolutions, and MBQ Pharma; received payment or honoraria from Research To Practice, Scripps, and MJH; and has stock options in Triumvira, Actym, and MBQ Pharma. JMM received research funding from ASTEX; payment or honoraria from Bristol Myers Squibb; travel support for meeting attendance from GSK; and participated on a Data Safety Monitoring Board or advisory board for Regeneron Pharmaceuticals. DB has nothing to disclose. AP received research funding from GSK. KYC has nothing to disclose. JW received consulting fees from Kanaph Therapeutics and Fusion Pharma; speaker’s bureau and honoraria from AstraZeneca and Eisai. GF received royalties from Wolters Kluwer UK; held an advisory role for AbbVie, Fujifilm, Silicon, Navire, Turning Point, Predicine, Inspirna, Regeneron, Jubilant, BostonGene, Teon, Merck, Sanofi, BridgeBio, and EMD Serono; Speaker’s honorarium from Total Health Conferencing and Rocky Mountain Oncology Society; travel support from Amgen, Bristol Myers Squibb, EMD Serono, Fujifilm, Millennium, Sarah Cannon Research Institute, and Synthorx/Sanofic; received research funding from 3-V Biosciences, Abbisko, Abbvie, ABL Bio, ADC Therapeutics, Accutar, Agenus, Aileron, American Society of Clinical Oncology, Amgen, ARMO/Eli Lilly, Artios, AstraZeneca, Bayer, BeiGene, Bioatla, Bioinvent, Biothera, Bicycle, Black Diamond, Boehringer Ingelheim, Celgene, Celldex, Ciclomed, Curegenix, Curis, Cyteir, Daiichi, DelMar, eFFECTOR, Eli Lilly, EMD Serono, Epizyme, Erasca, Exelixis, Freenome, Fujifilm, Genmab, GSK, Hutchison MediPharma, IGM Biosciences, Ignyta, Immunitas, ImmunoGen/MacroGenics, Incyte, Jacobio, Jazz, Jounce, Jubilant, Kineta, Kolltan, Loxo/Bayer, MedImmune, Merck, Metabomed, Millennium, Mirati, miRNA Therapeutics, Molecular Templates, National Institutes of Health, Navire/BridgeBio, NGM Bio, NiKang, Novartis, OncoMed, Oncorus, Oncothyreon, Poseida, Precision Oncology, Prelude, PureTech, Pyramid, Pyxis, RasCal, Regeneron, Relay, Rgenix, Ribon, Roche, Samumed, Sapience, Seagen, Silicon, Simcha, Sirnaomics, Strategia, Syndax, Synthorx/Sanofi, Taiho, Takeda, Tallac, Tarus, Tarveda, Teneobio, Tesaro, Tocagen, Turning Point, U.T. MD Anderson Cancer Center, Vegenics, Xencor, and Zhuhai Yufan. JMC received research funding from Merus, Roche, Servier, and Bristol Myers Squibb; research support from Merck, AstraZeneca, Esperas Pharma, Bayer, Tesaro, Arcus Biosciences, and Apexigen; honoraria for advisory board participation from Incyte and Blueprint Medicines; and has given educational talks sponsored by Bayer, Merck, AstraZeneca, and Genentech. RK received consulting/advisory fees from AstraZeneca, Exelixis, Ipsen, Eisai, Roche, and Pfizer; and speaker’s bureau fees from Incyte and AstraZeneca. AK has nothing to disclose. OM has nothing to disclose. HY is an employee of GSK; and holds stock/shares with GSK and Treos Bio Limited. CE is an employee of and holds stocks/shares with GSK. AW is an employee of GSK. SG is an employee of GSK. HZ is an employee of GSK. KY is an employee of GSK. SDS is an employee of GSK. IDP is an employee of and holds stocks/shares with GSK. SU received support for the present manuscript from GSK and Tesaro; received grants from AbbVie Inc, Adlai Nortye, ArQule Inc, Artios, AstraZeneca, Atreca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Ciclomed LLC, Erasca, Evelo, Exelexis, G1 Therapeutics Inc, GSK, IGM Biosciences, Immunitas, Incyte, Isofol, Klus Pharma Inc, Macrogenics, Merck Co. Inc, Mersana Therapeutics, OncoMed Pharmaceuticals Inc, Pfizer, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Synermore Biologics, Takeda, Tarveda, Tesaro, Tempest Therapeutics, Tvardi, and Vigeo Therapeutics; and participated on a Data Safety Monitoring Board or advisory board for Eisai, AstraZeneca, and IGM biosciences.